We provide you with 20 years of free, institutional-grade data for KZIA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KZIA. Explore the full financial landscape of KZIA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Kazia Therapeutics Limited(NASDAQ:KZIA) 
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also dev...
The information provided in this report about KZIA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.